IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC).

Andreas Schneeweiss,Hope S. Rugo,Eric P. Winer,Carlos H. Barrios,Hiroji Iwata,Véronique Diéras,Sherene Loi,Vidya Maiya,John Bond,Guiyuan Lei,Stephen Y. Chui,Sylvia Adams,Leisha A. Emens,Peter Schmid

IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC).

2019

Andreas Schneeweiss
Hope S. Rugo
Eric P. Winer
Carlos H. Barrios
Hiroji Iwata
Véronique Diéras
Sherene Loi
Vidya Maiya
John Bond
Guiyuan Lei
Stephen Y. Chui
Sylvia Adams
Leisha A. Emens
Peter Schmid

1068Background: IMpassion130 showed PFS benefit with A + nP vs placebo (P) + nP as 1L tx for mTNBC in the ITT and PD-L1 IC+ pts. We report expanded safety data with 4.5-mo longer follow-up (FU), fo...

Keywords:

Placebo
Nab-paclitaxel
Oncology
Pathology
Triple-negative breast cancer
Medicine
Atezolizumab
Internal medicine
in patient
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations